Catalent unveiled a collaboration with Galapagos to support decentralized manufacturing for clinical studies of the Belgium-based biotech’s investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma indications.
Catalent’s commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing of GLPG5101, a CD19 CAR T cell therapy, for Galapagos’ upcoming trials in New Jersey, New York and surrounding areas. Last month, the biotech shared data from the ongoing phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population, demonstrating high antitumor activity and an encouraging safety profile in all NHL subtypes studied.
Galapagos uses its decentralized cell therapy manufacturing platform to bring the manufacturing process closer to patients, offering the potential to deliver fresh, fit, stem-like early memory T cells with a median vein-to-vein time of seven days. This avoids cryopreservation and eliminates the need for bridging therapy.
Earlier this month, Galapagos announced it would separate into two entities: one focused on building a pipeline of innovative medicines through strategic transactions and one which will keep the Galapagos name and continue to use Galapagos’ decentralized cell therapy manufacturing platform in oncology. The split came with 40% workforce reduction.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!